BHCM
LBRX

Brevan Howard Capital Management’s LB Pharmaceuticals LBRX Stock Holding History

Brevan Howard Capital Management’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,259
Closed -$209K – 2366
2025
Q3 		$209K Buy
+13,259
New +$210K ﹤0.01% 1729

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM

Brevan Howard Capital Management's LBRX Position: Q4 2025 in Review

Brevan Howard Capital Management sold out of LB Pharmaceuticals (LBRX) in Q4 2025, closing a stake of 13,259 shares — an estimated $209K sold.

Brevan Howard Capital Management first reported a position in LBRX in Q3 2025 and held it in 1 quarter. The position peaked at $209K in Q3 2025. 68 funds tracked by Wall St. Rank hold LBRX as of Q4 2025.

  • Brevan Howard Capital Management reported no remaining LB Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 13,259 LB Pharmaceuticals shares in Q4 2025, an estimated $209K.
  • Brevan Howard Capital Management first reported a position in LB Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Brevan Howard Capital Management's LB Pharmaceuticals position peaked at $209K in Q3 2025.
  • 68 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q4 2025.

Based on Brevan Howard Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.